Hallucinations in Parkinson disease in the prelevodopa era
University of Cologne, Köln, North Rhine-Westphalia, Germany Neurology
(Impact Factor: 8.29).
02/2006; 66(1):93-8. DOI: 10.1212/01.wnl.0000191325.31068.c4
Whether chronic hallucinations belong to the natural history of untreated Parkinson disease (PD) remains undetermined. For early authors such as Gowers or Charcot and his followers, hallucinations that occurred in the course of PD either accompanied the final phase of the disease or reflected comorbidities. However, a few authors observed that hallucinations could occur in PD patients with severe depression, confusion, or dementia. Interest in hallucinations with parkinsonism increased with the outbreak of von Economo encephalitis, as they were more frequent than in PD, provoking new pathophysiologic questions. Later studies on mental symptoms in parkinsonism were often based on series that pooled patients with PD and postencephalitic syndromes, confounding a clear analysis. It remains difficult to estimate the prevalence of hallucinations in the natural course of PD before the introduction of levodopa therapy. The lack of prospective studies, the wide early use of anticholinergics and ergots compounds, and the absence of dementia with Lewy bodies in the nosology of the time are further limitations. Even with these limitations, historical descriptions of PD from the prelevodopa era suggest that hallucinations may be part of PD itself, especially in the context of late dementia, depression, or nonspecific encephalopathy.
Available from: Michele Poletti
- "Psychosis in PD is usually confirmed using the Parkinson’s Psychosis Rating Scale (Friedberg et al., 1998). Although it was previously found that the administration of dopaminergic drugs is the main cause of psychosis and hallucinations (Morgante et al., 2012), recent studies additionally show that sleep disturbance, dementia, longer disease duration, and advanced stage of the disease, can also exacerbate psychotic symptoms in PD patients (Poewe, 2003; Fenelon et al., 2006; Fenelon, 2008; Bannier et al., 2012; Gibson et al., 2013; Lee and Weintraub, 2012; Morgante et al., 2012). So unlike earlier clinical practice, a diagnosis of psychosis in PD is made when the patients have not had any dopaminergic medications. "
[Show abstract] [Hide abstract]
ABSTRACT: Parkinson's disease (PD) is a neurological disorder, associated with rigidity, bradykinesia, and resting tremor, among other motor symptoms. In addition, patients with PD also show cognitive and psychiatric dysfunction, including dementia, mild cognitive impairment (MCI), depression, hallucinations, among others. Interestingly, the occurrence of these symptoms-motor, cognitive, and psychiatric-vary among individuals, such that a subgroup of PD patients might show some of the symptoms, but another subgroup does not. This has prompted neurologists and scientists to subtype PD patients depending on the severity of symptoms they show. Neural studies have also mapped different motor, cognitive, and psychiatric symptoms in PD to different brain networks. In this review, we discuss the neural and behavioral substrates of most common subtypes of PD patients, that are related to the occurrence of: (a) resting tremor (vs. nontremor-dominant); (b) MCI; (c) dementia; (d) impulse control disorders (ICD); (e) depression; and/or (f) hallucinations. We end by discussing the relationship among subtypes of PD subgroups, and the relationship among motor, cognitive, psychiatric factors in PD.
Frontiers in Systems Neuroscience 12/2013; 7:117. DOI:10.3389/fnsys.2013.00117
Available from: Hideyuki Sawada
- "Although mild, simple visual hallucinations with retained insight do not require additional medical treatment, severe psychosis requires hospitalization and is associated with mortality . Although visual hallucinations are associated with PD brain pathology , they could be associated with dopaminergic replacement therapy , especially that involving dopamine agonists [7-9]. Antipsychotic drugs except for clozapine  improve psychosis insufficiently [11,12], but worsen motor symptoms . "
[Show abstract] [Hide abstract]
ABSTRACT: Psychoses such as hallucinations are a frequent non-motor problem in patients with Parkinson disease (PD) and serious psychosis requires anti-psychotic medications that worsen Parkinsonism. Although psychosis could be associated with patient-related or biological factors such as cognition, age, and severity of PD, it can also be associated with medications.Therefore we aimed to investigate patient-related and medication-related risks of psychosis requiring anti-psychotic medications (serious psychosis).
A retrospective cohort of 331 PD patients was followed for 2 years. Patient-related factors associated with risk of psychosis were identified by a survival time analysis. In patients who developed psychosis, medications during the hazard period (1-14 days before psychosis) were contrasted with those during the control periods (1 and 3 months before psychosis) using a case--crossover analysis to identify medication-related risks of psychosis.
Serious psychosis was detected in 52 patients and the incidence was estimated to be 116 (95% confidence interval [CI], 85-148) per 1,000 person-years. Analyses of baseline characteristics revealed the risk to be higher in patients with a modified Hoehn--Yahr stage of >=4 (hazard ratio [HR], 2.22; 95% CI, 1.11-4.40), those with a longer duration of PD (HR, 1.25; 95% CI, 1.00-1.55, per 5 years) and those with Mini-Mental State Examination scores of <=24 (HR, 2.66; 95% CI, 1.37-5.16). The case-crossover analysis revealed that anti-cholinergics use (HR, 19.7; 95% CI, 2.39-162) elevated the risk, while donepezil use reduced it (HR, 0.48; 95% CI, 0.27-0.85).
Risk of psychosis was elevated by increasing severity of PD, cognitive dysfunction and duration of the disease. It was elevated by use of anti-cholinergic drugs and reduced by use of donepezil. The medication-related risk was higher in patients aged >= 70 years. In contrast, there was no significant medication-related risk in younger patients, suggesting different pathomechanisms between young and old patients.
BMC Neurology 10/2013; 13(1):145. DOI:10.1186/1471-2377-13-145 · 2.04 Impact Factor
Available from: Grant Gibson
- "RESEARCH ARTICLE light, colour or shapes, and complex hallucinations, clearly formed objects, animals or humans or a sense of 'presence', characterised by a vivid sensation of somebody or something being nearby (Mossiman et al., 2008; Fenelon et al., 2011). Visual hallucinations have seen much study in PD, especially since the introduction of levodopa therapies (Fenelon et al., 2006). However, evidence for risk factors associated with VHs in PD varies considerably. "
[Show abstract] [Hide abstract]
ABSTRACT: To examine the prevalence, incidence and risk factors associated with visual hallucinations (VHs) amongst people suffering from Parkinson's disease (PD).
We recruited 513 patients with PD from movement disorder and PD clinics within three sites in the UK. Patients were interviewed using a series of standardised clinical rating scales at baseline, 12, 24 and 36 months. Data relating to VHs were collected using the North-East Visual Hallucinations Interview. Prevalence rates for VHs at each assessment were recorded. Associations were determined using multiple regression analysis.
Cross-sectional prevalence rates for VHs at baseline, 12, 24 and 36 months indicated VHs in approximately 50% of patients. A cumulative frequency of 82.7% of cases at the end of the study period exhibited VHs. The incidence rate for VHs was 457 cases per 1000 population. Longer disease duration, greater impairment in activities of daily living and higher rates of anxiety were most commonly associated with VHs. No factors predictive of VHs could be ascertained.
When examined longitudinally, VHs affect more patients than is commonly assumed in cross-sectional prevalence studies. Clinicians should routinely screen for VHs throughout the disease course. Disease duration, impairment in activities of daily living and anxiety presented as co-morbidities associated with VHs in PD, and therefore those presenting with VHs should be screened for anxiety disorder and vice versa. Copyright
International Journal of Geriatric Psychiatry 06/2013; 28(6). DOI:10.1002/gps.3869 · 2.87 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.